Hermetica Superfood Encyclopedia
The Short Answer
Calcium fructoborate delivers bioavailable boron primarily as diester (~85%), monoester (~10%), and free boric acid (~5%) in aqueous solution, modulating inflammatory enzyme cascades, reducing oxidative stress, and interacting with glycoproteins via a low pKa (4.16) ester form that confers superior cellular stability over inorganic boron sources. In a 30-day randomized, double-blind, placebo-controlled trial (n=84), 112 mg/day CFB significantly reduced IL-1β, IL-6, MCP-1 by 31%, CRP, homocysteine, LDL, triglycerides, and total cholesterol while increasing HDL (p<0.001 for key inflammatory markers).
CategoryMineral
GroupMineral
Evidence LevelPreliminary
Primary Keywordcalcium fructoborate benefits
Calcium Fructoborate — botanical close-up
Health Benefits
**Inflammatory Cytokine Reduction**: CFB at 112 mg/day reduced IL-1β from 8
2±9.3 to 6.7±7.8 and IL-6 comparably (p<0.001) in a 30-day RCT, suggesting meaningful suppression of pro-inflammatory signaling pathways relevant to joint and cardiovascular health.
**Cardiovascular Lipid Improvement**
Clinical data show significant reductions in LDL cholesterol, total cholesterol, and triglycerides alongside increased HDL with 112 mg/day CFB, pointing to a favorable modulation of lipid metabolism through boron-mediated enzyme regulation.
**Homocysteine Lowering**: Plasma homocysteine dropped from 3
2±2.6 to 2.0±1.8 µmol/L (p<0.001) in the CFB-1 group, a clinically relevant reduction given homocysteine's role as an independent cardiovascular and cognitive risk marker.
**MCP-1 and Monocyte Chemoattractant Suppression**
A 31% reduction in MCP-1 at 112 mg/day and 26% at 56 mg/day indicates dose-dependent attenuation of monocyte recruitment signals, potentially reducing atherosclerotic plaque progression and tissue inflammation.
**Joint and Connective Tissue Support**
Boron is known to influence calcium and magnesium metabolism, steroid hormone biosynthesis (including vitamin D and estrogen), and extracellular matrix glycoprotein integrity, all of which are mechanistically relevant to cartilage health and joint function.
**Oxidative Stress Modulation**
CFB's boron-containing esters engage antioxidant pathways intracellularly by reducing reactive oxygen species production, supporting mitochondrial energy metabolism and cellular redox homeostasis.
**Hormone Metabolism Regulation**
Boron delivered via CFB has been associated in broader boron literature with modulation of sex hormone-binding globulin (SHBG), testosterone, and estradiol levels, potentially supporting hormonal balance in both men and women, though direct CFB-specific hormone trial data remain limited.
Origin & History
Natural habitat
Calcium fructoborate (CFB) is a naturally occurring sugar-borate ester found endogenously in fruits, vegetables, nuts, seeds, and honey as part of the normal human dietary landscape. It is not cultivated from a single geographic source but is distributed broadly across plant foods worldwide, with dietary intake averaging approximately 35 mg CFB per day (~1.05 mg elemental boron) in typical Western diets. Commercial CFB is manufactured via a patented process (US Patent #5,962,049) that replicates the natural bis-fructose borate ester structure found in plant tissues, yielding a standardized powder form known as FruXB.
“Calcium fructoborate does not have a formalized history of use in classical herbal medicine systems such as Ayurveda, Traditional Chinese Medicine, or Western herbalism, as it was not isolated or identified as a distinct compound until the late 20th century. Its presence in human diets is, however, ancient and universal — fruits, vegetables, nuts, and honey containing naturally occurring fructoborate esters have been consumed by humans across all cultures throughout recorded history, making CFB a dietary constant rather than a targeted medicinal agent. The characterization of boron as a nutritionally relevant element gained scientific momentum in the 1980s–1990s when researchers identified its role in calcium metabolism, bone density, and hormonal regulation, laying the groundwork for CFB's commercial development. The compound was patented for commercial synthesis in 1999 (US Patent #5,962,049), representing a modern nutraceutical innovation that standardizes and concentrates a naturally occurring dietary constituent rather than a traditional remedy.”Traditional Medicine
Scientific Research
The primary clinical evidence base for CFB consists of at least one published randomized, double-blind, placebo-controlled trial (n=84 healthy subjects) demonstrating statistically significant reductions in inflammatory biomarkers (IL-1β, IL-6, MCP-1, CRP), cardiovascular risk markers (LDL, TG, TC, homocysteine), and increases in HDL at doses of 56–112 mg/day over 30 days (p<0.001 for key endpoints). While this trial represents a well-designed study with dose-response data across two active arms, the evidence base is currently limited in volume — only one published RCT with a relatively small sample size and short follow-up duration has been identified in the literature for this specific compound. Broader boron literature from multiple observational, preclinical, and some clinical studies supports the general biological plausibility of boron's anti-inflammatory, hormonal, and bone-supportive effects, lending indirect mechanistic credibility to CFB's proposed benefits. Direct replication studies, longer-duration trials, and investigation in clinical populations (e.g., osteoarthritis, metabolic syndrome) are needed before strong evidence-based clinical recommendations can be made.
Preparation & Dosage
Traditional preparation
**Powder (FruXB)**
The commercially validated form, characterized by X-ray diffraction (XRD), FTIR, Raman spectroscopy, and thermal analysis; typically encapsulated or blended into tablets.
**Clinical Dose — High**
112 mg/day CFB (providing ~2
8 mg elemental boron and ~5.2 mg calcium), the dose demonstrating the most robust clinical effects in the published 30-day RCT.
**Clinical Dose — Moderate**
56 mg/day CFB (providing ~1
4 mg elemental boron), showing statistically significant but slightly smaller effect sizes compared to the higher dose.
**Dietary Equivalent**
35 mg CFB (~1
Average daily dietary exposure is ~.05 mg B); supplement doses of 56–112 mg/day represent a 1.6–3.2× elevation above typical dietary intake.
**Regulatory Upper Limit**
20 mg elemental boron equivalents daily; CFB doses of 56–112 mg/day (1
Dietary supplement products are generally formulated to deliver ≤.4–2.8 mg B) fall well within this threshold.
**Timing**
No specific timing requirements have been established in published trials; with food is generally recommended to optimize gastrointestinal tolerance and calcium co-absorption.
**Duration**
Clinical evidence is based on 30-day supplementation; long-term dosing protocols have not been formally studied.
Nutritional Profile
Calcium fructoborate contributes two primary nutritionally active minerals per dose: elemental boron at approximately 2.5% by weight (yielding ~1.4–2.8 mg B per 56–112 mg dose) and elemental calcium at approximately 4.6% by weight (~2.6–5.2 mg Ca per dose). The fructose moiety of the ester is quantitatively minor and does not contribute meaningfully to carbohydrate or caloric intake at supplemental doses. Bioavailability of boron from CFB is considered high due to its water-soluble ester structure and natural identity with plant-derived borate esters; absorption is facilitated by passive diffusion and aquaporin-mediated transport. The compound provides no significant macronutrients, fat-soluble vitamins, or phytochemicals beyond its boron and calcium content, and its clinical value derives entirely from its unique molecular architecture rather than broad nutritional density.
How It Works
Mechanism of Action
At physiological pH 7.4, CFB exists predominantly (~85%) as a stable diester fructoborate with a pKa of 4.16, enabling superior covalent interaction with cis-diol-containing glycoproteins and enzyme cofactor sites compared to free boric acid (pKa 9.24), which predominates in inorganic boron sources. Elemental boron enters cells as uncharged boric acid via passive diffusion or aquaporin-3 transporters, where it acts as a Lewis acid to inhibit serine proteases, modulate NAD+/NADH-dependent enzymes, and suppress NF-κB-driven transcription of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α. Extracellularly, fructoborate esters interact with integrin-associated glycoproteins and extracellular matrix components, influencing cell adhesion, MCP-1 secretion, and lipid transport protein activity. Concurrent calcium delivery (4.6% by weight) supports intracellular signaling cascades, enzyme activation (including calmodulin-dependent kinases), and bone mineral metabolism, creating a dual-mineral synergistic effect on musculoskeletal and inflammatory endpoints.
Clinical Evidence
The pivotal CFB clinical trial enrolled 84 healthy adult subjects randomized to placebo, 56 mg/day CFB (CFB-2), or 112 mg/day CFB (CFB-1) for 30 days, measuring inflammatory cytokines, lipid panel, homocysteine, and cardiovascular biomarkers. The CFB-1 group demonstrated statistically significant improvements across all primary outcomes including a 31% reduction in MCP-1, significant decreases in IL-1β (8.2 to 6.7), IL-6, CRP, triglycerides, LDL, total cholesterol, and homocysteine (3.2 to 2.0 µmol/L), alongside increased HDL (all p<0.001). CFB-2 produced similar directional results with slightly attenuated magnitudes (e.g., 26% MCP-1 reduction), confirming a dose-dependent relationship. Confidence in these findings is moderate given the rigorous double-blind design, but is tempered by the single-trial status, healthy-subject population limiting generalizability to diseased individuals, and the 30-day observation window insufficient to assess long-term efficacy or safety.
Safety & Interactions
Calcium fructoborate is well-tolerated across the studied dose range of 56–112 mg/day (1.4–2.8 mg elemental boron), with no adverse events, drug interactions, or clinically significant side effects reported in the published 30-day RCT involving 84 subjects; broader safe intake ranges for boron supplementation are generally cited at 1–13 mg/day elemental boron for adults. The boron-oxygen ester bonds in CFB are stable and do not require hepatic metabolism, reducing the likelihood of reactive metabolite-related toxicity, though this stability has not been formally evaluated across special populations. No specific drug interactions have been documented for CFB; however, theoretical interactions with estrogen-modulating medications, anticoagulants, or drugs with narrow therapeutic indices are plausible given boron's known effects on steroid hormone metabolism and enzyme inhibition, and caution is warranted pending formal interaction studies. Safety data in pregnant or lactating women, pediatric populations, and individuals with renal impairment (who may accumulate boron due to reduced excretion) are absent, and use in these populations should be avoided until adequate safety evidence is established; the tolerable upper intake level for boron established by the Institute of Medicine is 20 mg/day for adults.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
FruXBbis-fructose borate esterBoron Fructose (Calcium Fructoborate)Ca[(C₆H₁₀O₆)₂B]₂·4H₂Ocalcium bis-fructofuranose borateCFBFructoborate (Calcium Fructoborate)
Frequently Asked Questions
What is calcium fructoborate used for?
Calcium fructoborate is used primarily to deliver highly bioavailable boron for joint support, anti-inflammatory effects, and cardiovascular health. In a 30-day randomized controlled trial, 112 mg/day reduced IL-1β, MCP-1 by 31%, LDL, triglycerides, and homocysteine significantly (p<0.001), while increasing HDL. It is also studied for hormone metabolism support, including modulation of vitamin D activation and sex hormone-binding globulin.
How does calcium fructoborate differ from regular boron supplements?
Unlike inorganic boron sources such as borax or boric acid, calcium fructoborate exists predominantly (~85%) as a stable diester fructoborate ester with a pKa of 4.16, which allows it to form stronger covalent interactions with glycoproteins and enzyme active sites at physiological pH compared to free boric acid (pKa 9.24). This unique molecular structure mirrors naturally occurring plant-derived borate esters, potentially conferring superior bioavailability and broader biological activity. The compound also co-delivers calcium (4.6% by weight), adding a secondary nutritional benefit absent from simple boron salts.
What is the recommended dosage of calcium fructoborate?
The clinically studied doses are 56 mg/day (CFB-2) and 112 mg/day (CFB-1), providing approximately 1.4 mg and 2.8 mg of elemental boron respectively, both tested over a 30-day period in a published double-blind RCT. The higher dose of 112 mg/day produced the most significant reductions in inflammatory markers and lipids. Both doses fall well within the tolerable upper intake level of 20 mg elemental boron per day established for adults.
Is calcium fructoborate safe to take daily?
Calcium fructoborate was well-tolerated with no reported adverse events in the published 30-day clinical trial at doses of 56–112 mg/day (1.4–2.8 mg elemental boron). The boron-oxygen ester bonds are chemically stable and do not require hepatic biotransformation, reducing metabolic toxicity risk. However, safety data for pregnant or lactating women, children, and individuals with kidney disease are lacking, and these populations should avoid use until formal safety studies are conducted.
Does calcium fructoborate help with joint pain?
Calcium fructoborate's joint support is mechanistically grounded in boron's role in maintaining extracellular matrix glycoprotein integrity, modulating calcium and magnesium metabolism, and suppressing pro-inflammatory cytokines (IL-1β, IL-6, MCP-1) that drive cartilage degradation. The published RCT demonstrated significant reductions in these inflammatory biomarkers at 56–112 mg/day in healthy subjects, which is consistent with reduced inflammatory burden relevant to joint tissues. Direct clinical trials in osteoarthritis or rheumatoid arthritis populations using CFB specifically have not yet been published, so joint-specific efficacy in diseased patients remains to be formally confirmed.
What does clinical research show about calcium fructoborate and inflammatory markers?
A 30-day randomized controlled trial demonstrated that calcium fructoborate at 112 mg/day significantly reduced inflammatory cytokines IL-1β and IL-6 (p<0.001), indicating meaningful suppression of pro-inflammatory signaling pathways. These reductions suggest potential relevance for managing joint and cardiovascular inflammation through evidence-based mechanisms rather than theoretical benefit alone.
Can calcium fructoborate help improve cholesterol and triglyceride levels?
Clinical data indicate that calcium fructoborate supplementation produces significant reductions in LDL cholesterol, total cholesterol, and triglycerides, making it potentially beneficial for cardiovascular lipid management. These improvements appear to work synergistically with its anti-inflammatory effects to support overall heart health markers.
Who should consider taking calcium fructoborate supplementation?
Calcium fructoborate may be most beneficial for individuals seeking to reduce inflammatory markers, support joint health, or improve cardiovascular lipid profiles through targeted boron supplementation. Those with elevated inflammatory cytokines or suboptimal cholesterol levels may experience the most meaningful results based on available clinical evidence.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w calcium-fructoborate curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
